CN109700777A - A kind of pH dependent form drug hydrophobic framework sustained release tablets and preparation method thereof - Google Patents
A kind of pH dependent form drug hydrophobic framework sustained release tablets and preparation method thereof Download PDFInfo
- Publication number
- CN109700777A CN109700777A CN201910145199.XA CN201910145199A CN109700777A CN 109700777 A CN109700777 A CN 109700777A CN 201910145199 A CN201910145199 A CN 201910145199A CN 109700777 A CN109700777 A CN 109700777A
- Authority
- CN
- China
- Prior art keywords
- sustained release
- release tablets
- framework
- dependent form
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of pH dependent form drug hydrophobic framework sustained release tablets and preparation method thereof, the raw material of the sustained release tablets includes: main ingredient, wax framework material, local pH adjusting agent, adhesive, filler, lubricant, glidant；The part pH adjusting agent is selected from calcium phosphate dibasic dihydrate, disodium hydrogen phosphate or calcium silicates.Preparation method is first to take wax framework material heating and melting, main ingredient, local pH adjusting agent, adhesive, filler is taken to be uniformly mixed again, then framework material and uniformly mixed material melts are pelletized, it is sieved while hot, whole grain, lubricant and glidant, tabletting is added after letting cool in standing, obtains the hydrophobic framework sustained release tablets.Local pH adjusting agent is added in hydrophobic framework sustained release tablets of the invention in the prescription of original diclofenac sodium extended action tablet, the pH value of microenvironment can be maintained to promote the dissolution of drug, to improve the release in vitro of pH dependent form drug.
Description
Technical field
The invention belongs to technical field of medicine, and in particular to a kind of pH dependent form drug hydrophobic framework sustained release tablets and its
Preparation method.
Background technique
Oral sustained release and controlled release preparation are a highly important directions of domestic and international medical industry development.Oral slow controlled release
1. preparation has the following characteristics that compared with common oral preparation to half-life short or needs the drug of frequent drug administration, it is possible to reduce give
Medicine number improves the compliance of patient, easy to use；2. keeping blood concentration steady, peak valley phenomenon is avoided, advantageously reduces drug
Adverse reaction；3. the accumulated dose of medication can be reduced, therefore available minimum dose reaches maximum drug effect.And since its research is opened
Send out that the period is short, economic risk is small, it is with high content of technology, lucrative and paid attention to by pharmaceuticals industry circle, it is current application and develops
More active system, and there are a considerable amount of controls, sustained release preparation to list.
Currently, the framework material being applied in sustained-release matrix tablets has hydrophilic gel matrix material, erodible framework material, no
Dissolubility framework material, mixed matrix material etc..Wherein hydrogel matrix kind is most, quickly grows, and most drugs can benefit
Sustained release preparation is made with it, hydroxypropyl methylcellulose, alginate, chitosan etc. is common hydrophilic gel matrix material, state
Interior most of sustained-release matrix tablets are made of using this hydrophilic gel matrix material, and for the research report of wax matrix sustained release tablet
Road is relatively fewer.Compared with the slow-release materials such as common cellulose family or polyacrylic, wax material has relative inertness, no
It is influenced, can effectively be blocked the advantages that burst release of water soluble drug by pH and moisture, and because its fusing point is lower, derived
The preparation method and production technology different from other slow-release material matrix tablets, it is easy to operate and at low cost, it has a wide range of applications
Prospect.The wax material that hydrophobic framework sustained release tablets mainly use such as palm wax, stearic acid, stearyl alcohol, polyethylene glycol, hydrogenated castor
Oil etc. is wrapped up drug by the methods of fusion method, solvent method, and drug is mainly discharged by duct diffusion or corrosion.But it is such
The problem of preparation cannot be discharged there may be part by packaging medicine completely.
Fusion method is the common method for preparing hydrophobic framework sustained release tablets, has following spy compared with traditional wet granulation
Point: it is 1. easy to operate, save liquid feeding and drying process；2. being suitable for the drug of hydrolabil；3. overcoming wet granulation easy to stick
The phenomenon that wall；4. being suitable for the preparation that water-insoluble material makees adhesive；5. preventing material dissolution in solvent.The technical process
Influence factor is numerous, and wherein heating temperature is key factor, and the too high or too low particle that is unfavorable for of heating temperature is formed.
Many drugs are since itself has faintly acid or alkalinity, and solubility and dissolution rate all have pH dependence, not
With in the medium of pH dissolution and dissolved corrosion have larger difference, therefore, this kind of drug discharges in the gastrointestinal tract and absorption is difficult to
Prediction.Organic acid or organic base would generally be added when designing prescription for such drug, to maintain the pH value of microenvironment, thus
Promote the dissolution of drug.
Bibliography:
Tirkkonen S, Urtti A, Paronen P. Buffer controlled release of
indomethacin from ethylcellulose microcapsules[J]. International Journal of
Pharmaceutics, 1995, 124(2):219–229.
Choi J S. Enhanced stability and solubility of pH-dependent drug,
Telmisartan achieved by solid dispersion[J]. 2017.
Wei Yabin, Chen Huiling take orally progress [J] gansu science and technology of sustained-release preparation, 2007,23 (8): 159-
162.
Zhang Y E, Schwartz J B. Melt Granulation and Heat Treatment for Wax
Matrix-Controlled Drug Release[J]. Drug Development & Industrial Pharmacy,
2003, 29(2):131.
Plateau, progress [J] Chinese Pharmaceutical Journal of Wang Hongguang melting high-speed stirred intermixture grain, 1999,34
(3):149-152.
Ning B, Liu X, Luan H, et al. Characterization of Multi-Sourced
Diclofenac Sodium Extended-Release Tablet Dissolution Profiles: A New
Approach to Establish an In vitro-In vivo Correlation Based on Multiple
Integral Response Surface[J]. Journal of Pharmaceutical Innovation, 2015, 10
(4):302-312。
Summary of the invention
Present invention aim to address existing pH dependent form drugs, and incomplete technical problem is discharged in sustained-release matrix tablets,
A kind of pH dependent form drug hydrophobic framework sustained release tablets and preparation method thereof are provided.
A kind of pH dependent form drug hydrophobic framework sustained release tablets, raw material include: main ingredient 30-35%, wax by weight percentage
Framework material 10-50%, local pH adjusting agent 0.5-10%, adhesive 0.5-10%, filler 30%-50%, lubricant 0.3-1%,
Glidant 0.3-1%；
The part pH adjusting agent is selected from calcium phosphate dibasic dihydrate, disodium hydrogen phosphate or calcium silicates.
Further, the main ingredient is C14H10Cl2NNaO2 or Metformin hydrochloride.
Further, it is sweet to be selected from hexadecanol, octadecyl alcolol, cetostearyl alcohol, paraffin or behenic acid for the wax framework material
Grease.
Further, described adhesive is selected from methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose or povidone.
Further, the lubricant is selected from talcum powder, superfine silica gel powder, magnesium stearate or stearic acid.
The preparation method of above-mentioned pH dependent form drug hydrophobic framework sustained release tablets, comprising the following steps:
Step 1, wax framework material heating and melting is taken, melt temperature is 40 ~ 80 DEG C；
Step 2, main ingredient, local pH adjusting agent, adhesive, filler are taken, is uniformly mixed；
Step 3, above-mentioned framework material and uniformly mixed material melts are pelletized, is sieved while hot, whole grain, standing is added after letting cool
Lubricant and glidant, tabletting obtain the hydrophobic framework sustained release tablets.
The utility model has the advantages that
1, local pH adjusting agent is added in hydrophobic framework sustained release tablets of the invention in the prescription of original diclofenac sodium extended action tablet,
The pH value of microenvironment can be maintained to promote the dissolution of drug, to improve the release in vitro of pH dependent form drug.
2, hydrophobic framework sustained release tablets of the invention eliminate coating steps by the local pH adjusting agent of addition in prescription,
Compared with the same specification diclofenac sodium extended action tablet listed, entire processing step is greatly simplified.And release in vitro performance
The experimental results showed that said preparation, which can reach, reaches same body with the same specification diclofenac sodium extended action tablet (Voltarol) listed
Outer releasing effect realizes 24 hours slow releases of drug.
3, said preparation is prepared by melt granulation, and the technological parameter for needing to control in whole process is relatively fewer, technique behaviour
Make it is relatively easy, be easy to industry amplification and actual production.
Detailed description of the invention
Fig. 1 be embodiment 1, in embodiment 2 and embodiment 3 diclofenac sodium extended action tablet in 6.8 dissolution medium of pH
Dissolution curve；
Fig. 2 is dissolution curve of the diclofenac sodium extended action tablet in pH6.8 dissolution medium in embodiment 4 and embodiment 5；
Fig. 3 is embodiment 6, dissolution of the diclofenac sodium extended action tablet in 6.8 dissolution medium of pH in embodiment 7 and embodiment 8
Curve；
Fig. 4 is dissolution curve of the diclofenac sodium extended action tablet in 6.8 dissolution medium of pH in Voltarol and embodiment 7.
Specific embodiment
Following embodiment further illustrates the contents of the present invention, but should not be construed as limiting the invention.Without departing substantially from
In the case where spirit of that invention and essence, to modification made by the method for the present invention, step or condition and replaces, belong to the present invention
Range.Unless otherwise specified, the conventional means that technological means used in embodiment is well known to those skilled in the art.
The present invention will be further elaborated below.
Steps are as follows for release in vitro performance measurement used by following embodiment:
(1) laboratory apparatus: RC806D dissolving-out tester (Tianda Tianfa Technology Co., Ltd.)；Vanquish Flex liquid
Chromatography (Thermo Scientific).(2) potassium dihydrogen phosphate 47.635g, sodium hydroxide the preparation of dissolution medium: are weighed
6.272g is dissolved in appropriate de aerated water, continues to be diluted to 7000ml to get pH6.8 phosphate buffer.(3) drug release determination
Method: taking tablet to be measured according to drug release determination method (USP38), using dissolution method second device, above-mentioned medium 900
ML, revolving speed be 50 rpm, temperature be (37 ± 0.5 DEG C), operate according to methods, respectively at 1h, 2h, 3h, 4h, 5h, 6h, 8h, 10h,
12h, 10 mL of solution is taken for 24 hours, filter, take subsequent filtrate as test solution, detect according to content assaying method in USP38, with medicine
Object cumulative percentage is plotted against time, and obtains vitro Drug dissolution curve.
Embodiment 1
Diclofenac sodium extended action tablet preparation method (specification is 100 mg)
Slice weight 291.3mg, C14H10Cl2NNaO2 100mg, hexadecanol (Cetyl alcohol) 60.56mg, sucrose 121.09mg gather
Tie up ketone (PVPK30) 4.69mg, magnesium stearate 2.48mg, silica 2.48mg.(1) the hexadecanol water-bath 70 of recipe quantity is weighed
DEG C heating is allowed to melt completely, spare；(2) C14H10Cl2NNaO2, sucrose, povidone (PVPK30) of recipe quantity are weighed, mixing is equal
It is even, it is spare；(3) supplementary material being uniformly mixed in (2) is poured into the hexadecanol melted completely, granulation, mistake is mixed in hot melt
18 meshes, the decentralization of particle room temperature is cold, and recipe quantity silica and magnesium stearate, tabletting is added.
As shown in Figure 1, release in vitro performance test the result shows that, the preparation of the present embodiment was presented at 24 hours and is slowly released
Medicine.
Embodiment 2
Diclofenac sodium extended action tablet preparation method (specification is 100 mg)
Slice weight 291.3mg, C14H10Cl2NNaO2 100mg, hexadecanol 80.57mg, sucrose 101.08mg, povidone (PVPK30)
4.69mg, magnesium stearate 2.48mg, silica 2.48mg.(1) the 70 DEG C of heating of hexadecanol water-bath for weighing recipe quantity have been allowed to
It is complete to melt, it is spare；(2) C14H10Cl2NNaO2, sucrose, povidone (PVPK30) of recipe quantity are weighed, is uniformly mixed, it is spare；(3) will
(2) supplementary material being uniformly mixed in pours into the hexadecanol melted completely, and granulation is mixed in hot melt, crosses 18 meshes, particle chamber
It is let cool under temperature, recipe quantity silica and magnesium stearate, tabletting is added.
As shown in Figure 1, release in vitro performance test the result shows that, the preparation of the present embodiment was presented at 24 hours and is slowly released
Medicine.
Embodiment 3
Diclofenac sodium extended action tablet preparation method (specification is 100 mg)
Slice weight 291.3mg, C14H10Cl2NNaO2 100mg, hexadecanol 58.76mg, octadecyl alcolol (Stearyl alcohol) 1.81mg,
Sucrose 121.10mg, povidone (PVPK30) 4.69mg, magnesium stearate 2.48mg, silica 2.48mg.(1) recipe quantity is weighed
Hexadecanol, 70 DEG C of octadecyl alcolol heating water bath be allowed to melt completely, it is spare；(2) weigh the C14H10Cl2NNaO2 of recipe quantity, sucrose,
Povidone (PVPK30) is uniformly mixed, spare；(3) by (2) be uniformly mixed supplementary material pour into the hexadecanol melted completely,
In octadecyl alcolol, granulation is mixed in hot melt, crosses 18 meshes, and the decentralization of particle room temperature is cold, and recipe quantity silica and stearic acid is added
Magnesium, tabletting.
As shown in Figure 1, release in vitro performance test the result shows that, the preparation of the present embodiment was presented at 24 hours and is slowly released
Medicine, but 24 hours accumulative release rates are too low, discharge too slow.
Embodiment 4
Diclofenac sodium extended action tablet preparation method (specification is 100 mg)
Slice weight 291.3mg, C14H10Cl2NNaO2 100mg, hexadecanol 58.76mg, octadecyl alcolol 1.81mg, sucrose 111.10mg, two water
Calcium monohydrogen phosphate (Calcium hydrogen phosphate dihydrate) 9.99mg, povidone (PVPK30) 4.69mg is closed,
Magnesium stearate 2.48mg, silica 2.48mg.(1) 70 DEG C of hexadecanol, octadecyl alcolol heating water bath for weighing recipe quantity has been allowed to
It is complete to melt, it is spare；(2) C14H10Cl2NNaO2, sucrose, calcium phosphate dibasic dihydrate, povidone (PVPK30) of recipe quantity are weighed, is mixed
Uniformly, spare；(3) supplementary material being uniformly mixed in (2) is poured into the hexadecanol melted completely, in octadecyl alcolol, hot melt mixing is stirred
Mixing grain crosses 18 meshes, and the decentralization of particle room temperature is cold, and recipe quantity silica and magnesium stearate, tabletting is added.
As shown in Fig. 2, release in vitro performance test the result shows that, the preparation of the present embodiment was presented at 24 hours and is slowly released
Medicine.
Embodiment 5
Diclofenac sodium extended action tablet preparation method (specification is 100 mg)
Slice weight 291.3mg, C14H10Cl2NNaO2 100mg, hexadecanol 58.76mg, octadecyl alcolol 1.81mg, sucrose 101.09mg, two water
Close calcium monohydrogen phosphate 20.01mg, povidone (PVPK30) 4.69mg, magnesium stearate 2.48mg, silica 2.48mg.(1) it weighs
70 DEG C of hexadecanol, the octadecyl alcolol heating water bath of recipe quantity is allowed to melt completely, spare；(2) weigh recipe quantity C14H10Cl2NNaO2,
Sucrose, calcium phosphate dibasic dihydrate, povidone (PVPK30) are uniformly mixed, spare；(3) supplementary material being uniformly mixed in (2) is fallen
Enter the hexadecanol melted completely, in octadecyl alcolol, granulation is mixed in hot melt, crosses 18 meshes, and the decentralization of particle room temperature is cold, and prescription is added
Measure silica and magnesium stearate, tabletting.
As shown in Fig. 2, release in vitro performance test the result shows that, the preparation of the present embodiment was presented at 24 hours and is slowly released
Medicine.
Embodiment 6
Diclofenac sodium extended action tablet preparation method (specification is 100 mg)
Slice weight 291.3mg, C14H10Cl2NNaO2 100mg, hexadecanol 58.74mg, octadecyl alcolol 1.82mg, sucrose 118.76mg, silicic acid
Calcium (Calcium silicate) 1.46mg, povidone (PVPK30) 4.69mg, magnesium stearate 2.91mg, silica
2.91mg.(1) 70 DEG C of hexadecanol, octadecyl alcolol heating water bath for weighing recipe quantity is allowed to melt completely, spare；(2) prescription is weighed
The C14H10Cl2NNaO2 of amount, sucrose, calcium silicates, povidone (PVPK30) are uniformly mixed, spare；(3) by (2) be uniformly mixed
Supplementary material pours into the hexadecanol melted completely, in octadecyl alcolol, and granulation is mixed in hot melt, crosses 18 meshes, and the decentralization of particle room temperature is cold,
Recipe quantity silica and magnesium stearate, tabletting is added.
As shown in figure 3, release in vitro performance test the result shows that, the preparation of the present embodiment was presented at 24 hours and is slowly released
Medicine.
Embodiment 7
Diclofenac sodium extended action tablet preparation method (specification is 100 mg)
Slice weight 291.3mg, C14H10Cl2NNaO2 100mg, hexadecanol 58.74mg, octadecyl alcolol 1.82mg, sucrose 112.35mg, silicic acid
Calcium 7.87mg, povidone (PVPK30) 4.69mg, magnesium stearate 2.91mg, silica 2.91mg.(1) the ten of recipe quantity are weighed
Six alcohol, 70 DEG C of octadecyl alcolol water-bath heating are allowed to melt completely, spare；(2) C14H10Cl2NNaO2, sucrose, silicic acid of recipe quantity are weighed
Calcium, povidone (PVPK30) are uniformly mixed, spare；(3) supplementary material being uniformly mixed in (2) is poured into 16 melted completely
In alcohol, octadecyl alcolol, granulation is mixed in hot melt, crosses 18 meshes, and the decentralization of particle room temperature is cold, and recipe quantity silica and tristearin is added
Sour magnesium, tabletting.
As shown in figure 3, release in vitro performance test the result shows that, the preparation of the present embodiment was presented at 24 hours and is slowly released
Medicine, the small time slice type of release in vitro 24 are complete.
Dissolution curve phase is carried out according to normal oral solid pharmaceutical preparation Dissolution Rate Testing technological guidance's principle that CFDA is promulgated
It is evaluated like property, as shown in figure 4, preparation (Optimized fumulation) In-vitro release curves and Voltarol of the present embodiment
(Voltaren) closest.
Embodiment 8
Diclofenac sodium extended action tablet preparation method (specification is 100 mg)
Slice weight 291.3mg, C14H10Cl2NNaO2 100mg, hexadecanol 58.74mg, octadecyl alcolol 1.82mg, sucrose 102.48mg, silicic acid
Calcium 16.02mg, povidone (PVPK30) 6.41mg, magnesium stearate 2.91mg, silica 2.91mg.(1) recipe quantity is weighed
Hexadecanol, 70 DEG C of octadecyl alcolol water-bath heating are allowed to melt completely, spare；(2) C14H10Cl2NNaO2, sucrose, silicon of recipe quantity are weighed
Sour calcium, povidone (PVPK30) are uniformly mixed, spare；(3) supplementary material being uniformly mixed in (2) is poured into ten melted completely
In six alcohol, octadecyl alcolol, granulation is mixed in hot melt, crosses 18 meshes, and the decentralization of particle room temperature is cold, and recipe quantity silica and hard is added
Fatty acid magnesium, tabletting.
As shown in figure 3, release in vitro performance test the result shows that, the agent in vitro of the present embodiment discharges 24 small time slice types not
Completely, and the release of the first six hour is too fast, there is phenomenon of burst release.
Claims (6)
1. a kind of pH dependent form drug hydrophobic framework sustained release tablets, it is characterised in that: raw material includes: main ingredient by weight percentage
30-35%, wax framework material 10-50%, local pH adjusting agent 0.5-10%, adhesive 0.5-10%, filler 30%-50%, profit
Lubrication prescription 0.3-1%, glidant 0.3-1%；
The part pH adjusting agent is selected from calcium phosphate dibasic dihydrate, disodium hydrogen phosphate or calcium silicates.
2. pH dependent form drug hydrophobic framework sustained release tablets according to claim 1, it is characterised in that: the main ingredient is double chlorine
Fragrant acid sodium or Metformin hydrochloride.
3. pH dependent form drug hydrophobic framework sustained release tablets according to claim 1, it is characterised in that: the wax skeleton material
Material is selected from hexadecanol, octadecyl alcolol, cetostearyl alcohol, paraffin or Compritol 888 ATO.
4. pH dependent form drug hydrophobic framework sustained release tablets according to claim 1, it is characterised in that: described adhesive is selected from
Methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose or povidone.
5. pH dependent form drug hydrophobic framework sustained release tablets according to claim 1, it is characterised in that: the lubricant is selected from
Talcum powder, superfine silica gel powder, magnesium stearate or stearic acid.
6. the preparation method of pH dependent form drug hydrophobic framework sustained release tablets described in claim 1, it is characterised in that: including following
Step:
Step 1, wax framework material heating and melting is taken, melt temperature is 40-80 DEG C；
Step 2, main ingredient, local pH adjusting agent, adhesive, filler are taken, is uniformly mixed；
Step 3, above-mentioned framework material and uniformly mixed material melts are pelletized, is sieved while hot, whole grain, standing is added after letting cool
Lubricant and glidant, tabletting obtain the hydrophobic framework sustained release tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910145199.XA CN109700777B (en) | 2019-02-27 | 2019-02-27 | PH-dependent drug hydrophobic skeleton sustained-release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910145199.XA CN109700777B (en) | 2019-02-27 | 2019-02-27 | PH-dependent drug hydrophobic skeleton sustained-release tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109700777A true CN109700777A (en) | 2019-05-03 |
| CN109700777B CN109700777B (en) | 2021-06-22 |
Family
ID=66265238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910145199.XA Active CN109700777B (en) | 2019-02-27 | 2019-02-27 | PH-dependent drug hydrophobic skeleton sustained-release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109700777B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111450069A (en) * | 2020-04-02 | 2020-07-28 | 南京致中生物科技有限公司 | Metformin hydrochloride oral sustained-release tablet and preparation method thereof |
| CN114053235A (en) * | 2020-08-07 | 2022-02-18 | 广州白云山光华制药股份有限公司 | Theophylline sustained release tablet and preparation method thereof |
| CN116251070A (en) * | 2021-12-10 | 2023-06-13 | 燃点(南京)生物医药科技有限公司 | Diclofenac sodium sustained release tablet and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274200A (en) * | 2011-08-10 | 2011-12-14 | 深圳致君制药有限公司 | Diclofenac sodium sustained release tablets and preparation process thereof |
| CN102871982A (en) * | 2012-10-16 | 2013-01-16 | 中国科学院上海药物研究所 | Medicine osmotic pump preparation |
| CN103169680A (en) * | 2012-12-07 | 2013-06-26 | 深圳市国源药业有限公司 | Diclofenac sodium sustained-release tablet and method for preparing same |
| CN103260607A (en) * | 2010-11-29 | 2013-08-21 | 泰姆勒集团股份有限责任公司 | Process for the preparation of a PPI-containing pharmaceutical product |
| EP2638898A1 (en) * | 2012-03-16 | 2013-09-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Metformin and Pioglitazone Formulation with Different Release Profiles |
| CN104127377A (en) * | 2014-08-04 | 2014-11-05 | 珠海亿胜生物制药有限公司 | Diclofenac sodium eye drops containing no antimicrobial agent and preparation method thereof |
| CN108785263A (en) * | 2017-04-26 | 2018-11-13 | 江苏恒瑞医药股份有限公司 | The solid composite medicament and preparation method thereof of Pramipexole or its pharmaceutical salts |
-
2019
- 2019-02-27 CN CN201910145199.XA patent/CN109700777B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103260607A (en) * | 2010-11-29 | 2013-08-21 | 泰姆勒集团股份有限责任公司 | Process for the preparation of a PPI-containing pharmaceutical product |
| CN102274200A (en) * | 2011-08-10 | 2011-12-14 | 深圳致君制药有限公司 | Diclofenac sodium sustained release tablets and preparation process thereof |
| EP2638898A1 (en) * | 2012-03-16 | 2013-09-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Metformin and Pioglitazone Formulation with Different Release Profiles |
| CN102871982A (en) * | 2012-10-16 | 2013-01-16 | 中国科学院上海药物研究所 | Medicine osmotic pump preparation |
| CN103169680A (en) * | 2012-12-07 | 2013-06-26 | 深圳市国源药业有限公司 | Diclofenac sodium sustained-release tablet and method for preparing same |
| CN104127377A (en) * | 2014-08-04 | 2014-11-05 | 珠海亿胜生物制药有限公司 | Diclofenac sodium eye drops containing no antimicrobial agent and preparation method thereof |
| CN108785263A (en) * | 2017-04-26 | 2018-11-13 | 江苏恒瑞医药股份有限公司 | The solid composite medicament and preparation method thereof of Pramipexole or its pharmaceutical salts |
Non-Patent Citations (4)
| Title |
|---|
| ABD EL-HALIM, S M: "Comparative study on the different techniques for the preparation of sustained-release hydrophobic matrices of a highly water-soluble drug", 《DRUG DISCOVERIES & THERAPEUTICS》 * |
| 恽琴素: "应用十六醇与ＨＰＭＣ 制备双氯芬酸钠缓释片的研究", 《海峡药学》 * |
| 罗明生: "《药剂辅料大全》", 31 January 2016, 四川科学技术出版社 * |
| 蒋露: "蜡质骨架片的研究进展", 《中国药科大学学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111450069A (en) * | 2020-04-02 | 2020-07-28 | 南京致中生物科技有限公司 | Metformin hydrochloride oral sustained-release tablet and preparation method thereof |
| CN114053235A (en) * | 2020-08-07 | 2022-02-18 | 广州白云山光华制药股份有限公司 | Theophylline sustained release tablet and preparation method thereof |
| CN116251070A (en) * | 2021-12-10 | 2023-06-13 | 燃点(南京)生物医药科技有限公司 | Diclofenac sodium sustained release tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109700777B (en) | 2021-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6949487B2 (en) | Regulated release formulation of pridopidin | |
| FI94923C (en) | Method of preparing a liquid dosage form for oral administration of a pharmaceutically active substance | |
| CN109700777A (en) | A kind of pH dependent form drug hydrophobic framework sustained release tablets and preparation method thereof | |
| Ishida et al. | A novel approach to sustained pseudoephedrine release: differentially coated mini-tablets in HPMC capsules | |
| Yadav et al. | Dual coating of swellable and rupturable polymers on Glipizide loaded MCC pellets for pulsatile delivery: Formulation design and in vitro evaluation | |
| HU229344B1 (en) | Coating and binding agent for pharmaceutical formulations with improved storage stability | |
| JP2008542312A (en) | Solid pharmaceutical composition having a first fraction of a dispersion medium and a second fraction of a matrix, wherein the second fraction is first at least partially exposed to gastrointestinal fluid | |
| JPS629A (en) | Sustained release compound unit pharmaceutical | |
| JPS611613A (en) | Oral drug composition of drug with low dissolution | |
| WO2000009133A1 (en) | Sustained release oral preparations of fasudil hydrochloride | |
| Singh et al. | Optimization studies on design and evaluation of orodispersible pediatric formulation of indomethacin | |
| Abdelkader et al. | Formulation of controlled-release baclofen matrix tablets II: influence of some hydrophobic excipients on the release rate and in vitro evaluation | |
| Wagner et al. | Development of disintegrating multiple-unit tablets on a high-speed rotary tablet press | |
| US20190240160A1 (en) | Acid resistant capsules | |
| Chivate et al. | Evaluation of Sterculia foetida gum as controlled release excipient | |
| JP2000128774A (en) | Production of globular, fine grain including medicine | |
| Badshah et al. | Development of controlled-release matrix tablet of risperidone: influence of methocel®-and ethocel®-based novel polymeric blend on in vitro drug release and bioavailability | |
| Rahmani et al. | The recent insight in the release of anticancer drug loaded into PLGA microspheres | |
| Ibrahim | Formulation and evaluation of mefenamic acid sustained release matrix pellets | |
| CN109771386A (en) | A kind of Flupentixol and Melitracen Tablets agent and preparation method thereof | |
| CN105343028A (en) | Medicine composition with norfloxacin and method for preparing medicine composition | |
| Leucuta | Controlled release of nifedipine from gelatin microspheres and microcapsules: in vitro kinetics and pharmacokinetics in man | |
| Waters et al. | In vitro controlled drug release from loaded microspheres-dose regulation through formulation | |
| Kadam et al. | Formulation and evaluation of colon targeted enteric coated tablets of loperamide | |
| Endale et al. | Granulation by roller compaction and enteric coated tablet formulation of the extract of the seeds of glinus lotoides loaded on Aeroperl® 300 Pharma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |